CL2025002505A1 - Compuestos derivados de pirazolopirimidina inhibidores del inflamasoma nlrp3. - Google Patents
Compuestos derivados de pirazolopirimidina inhibidores del inflamasoma nlrp3.Info
- Publication number
- CL2025002505A1 CL2025002505A1 CL2025002505A CL2025002505A CL2025002505A1 CL 2025002505 A1 CL2025002505 A1 CL 2025002505A1 CL 2025002505 A CL2025002505 A CL 2025002505A CL 2025002505 A CL2025002505 A CL 2025002505A CL 2025002505 A1 CL2025002505 A1 CL 2025002505A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibit
- nlrp3 inflammasome
- derivative compounds
- pyrazolopyrimidine derivative
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023027432 | 2023-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2025002505A1 true CL2025002505A1 (es) | 2025-11-14 |
Family
ID=92501386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025002505A CL2025002505A1 (es) | 2023-02-24 | 2025-08-20 | Compuestos derivados de pirazolopirimidina inhibidores del inflamasoma nlrp3. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4671247A1 (https=) |
| JP (2) | JP7737490B2 (https=) |
| KR (1) | KR20250151389A (https=) |
| CN (1) | CN120752239A (https=) |
| AR (1) | AR131919A1 (https=) |
| AU (1) | AU2024226032A1 (https=) |
| CL (1) | CL2025002505A1 (https=) |
| CO (1) | CO2025011311A2 (https=) |
| IL (1) | IL322520A (https=) |
| MX (1) | MX2025009965A (https=) |
| PE (1) | PE20252572A1 (https=) |
| TW (1) | TW202448887A (https=) |
| WO (1) | WO2024177127A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025140708A1 (zh) * | 2023-12-31 | 2025-07-03 | 杭州百新生物医药科技有限公司 | 吡唑并嘧啶类化合物及其医药用途 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20191679T1 (hr) * | 2013-10-30 | 2019-12-13 | Shanghai hengrui pharmaceutical co ltd | Derivati pirazolopirimidona ili pirolotriazona, postupak pripreme jednakih i njihove farmaceutske uporabe |
| WO2017205766A1 (en) * | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2020150114A1 (en) * | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Heterocyclic nlrp3 modulators, for use in the treatment of cancer |
| US12391675B2 (en) * | 2019-01-14 | 2025-08-19 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| CN114829345A (zh) * | 2019-12-27 | 2022-07-29 | 日本烟草产业株式会社 | 酰基磺酰胺化合物及其医药用途 |
| US20240382488A1 (en) * | 2021-03-29 | 2024-11-21 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2022216680A1 (en) * | 2021-04-05 | 2022-10-13 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| CA3229401A1 (en) * | 2021-08-31 | 2023-03-09 | Japan Tobacco Inc. | 6-aminopyrazolopyrimidine compounds and medical use thereof |
| US20250114361A1 (en) * | 2022-08-29 | 2025-04-10 | Japan Tobacco Inc. | Pyrazolopyrimidine compound and pharmaceutical use thereof |
| KR20250170647A (ko) * | 2023-04-14 | 2025-12-05 | 다케다 야쿠힌 고교 가부시키가이샤 | Nlrp3 억제제로서의 피라졸로피리미딘 유도체 |
-
2024
- 2024-02-22 IL IL322520A patent/IL322520A/en unknown
- 2024-02-22 WO PCT/JP2024/006433 patent/WO2024177127A1/ja not_active Ceased
- 2024-02-22 PE PE2025001836A patent/PE20252572A1/es unknown
- 2024-02-22 AU AU2024226032A patent/AU2024226032A1/en active Pending
- 2024-02-22 EP EP24760425.9A patent/EP4671247A1/en active Pending
- 2024-02-22 CN CN202480014319.1A patent/CN120752239A/zh active Pending
- 2024-02-22 JP JP2024025063A patent/JP7737490B2/ja active Active
- 2024-02-22 KR KR1020257027024A patent/KR20250151389A/ko active Pending
- 2024-02-22 AR ARP240100407A patent/AR131919A1/es unknown
- 2024-02-22 TW TW113106397A patent/TW202448887A/zh unknown
-
2025
- 2025-08-20 CL CL2025002505A patent/CL2025002505A1/es unknown
- 2025-08-21 CO CONC2025/0011311A patent/CO2025011311A2/es unknown
- 2025-08-22 MX MX2025009965A patent/MX2025009965A/es unknown
- 2025-08-29 JP JP2025143871A patent/JP2025176085A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250151389A (ko) | 2025-10-21 |
| CO2025011311A2 (es) | 2025-09-08 |
| AU2024226032A1 (en) | 2025-09-11 |
| AR131919A1 (es) | 2025-05-14 |
| EP4671247A1 (en) | 2025-12-31 |
| JP7737490B2 (ja) | 2025-09-10 |
| TW202448887A (zh) | 2024-12-16 |
| CN120752239A (zh) | 2025-10-03 |
| JP2025176085A (ja) | 2025-12-03 |
| IL322520A (en) | 2025-10-01 |
| MX2025009965A (es) | 2025-09-02 |
| PE20252572A1 (es) | 2025-10-28 |
| JP2024120882A (ja) | 2024-09-05 |
| WO2024177127A1 (ja) | 2024-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025002505A1 (es) | Compuestos derivados de pirazolopirimidina inhibidores del inflamasoma nlrp3. | |
| CO2026004076A2 (es) | Compuestos macrocíclicos, método de preparación de estos y uso de estos | |
| CO2022003782A2 (es) | Inhibidores de kras g12d | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2023008167A2 (es) | Inhibidores de prmt5 | |
| DOP2025000288A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| CO2026004964A2 (es) | Moduladores de kras | |
| MX2024010399A (es) | Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias | |
| AR119207A1 (es) | DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR | |
| CO2022017622A2 (es) | Inhibidores de quinasa nek7 | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| CO2024015820A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| UY30912A1 (es) | Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso. | |
| CO2024015816A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| BR112023019435A2 (pt) | Inibidores de nek7 | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| MX2024008629A (es) | Derivados del azaindol y su uso como inhibidores de la erk-cinasa. | |
| CO2022019131A2 (es) | Inhibidores de la quinasa nek7 | |
| ECSP22049160A (es) | Derivados de bencimidazol | |
| UY40457A (es) | Inhibidores de tead y métodos de uso de los mismos | |
| CL2024002379A1 (es) | Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso | |
| BR112022000155A2 (pt) | Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma | |
| MX2021011979A (es) | Derivados del isocromeno como inhibidores de la fosfoinositida 3-cinasa. | |
| ECSP23075535A (es) | Compuestos cíclicos y métodos de uso |